The company is primed to launch a Phase I clinical study, aiming to assess the safety, tolerability, and preliminary efficacy of SPX-303 in patients beleaguered by advanced or refractory solid tumors.
[SparX Biopharmaceutical Corp. (Cision Newswire)]